(All figures are presented in U.S. dollars) Cash on hand grew by $4.6 million to $33.4 million EPS increased 25% year-over-year to $0.10 Adjusted EBITDA1 of $3.2 million was higher than Q1 2022...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the first quarter of 2023 on Thursday, May 11, 2023. The Company...

Mississauga, Ontario--(Newsfile Corp. - April 18, 2023) - Cipher Pharmaceuticals (TSX: CPH), a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage...

(All figures are in U.S. dollars) Product revenue increased 9% to $12.5 million in 2022 EBITDA of $12.0 million, relatively flat YoY Cash at December 31, 2022 was $28.8 million (CDN$39 million) or...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the three and twelve months ended December 31, 2022 after market...